GENE ONLINE|News &
Opinion
Blog

Licensing
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
AstraZeneca Blocks Ionis’ Hypercholesterolemia Treatment from Moving into a Phase 3 Study
2022-09-23
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
GSK Puts Up $100 Million for Mersana’s HER2-Targeting ADC Candidate
2022-08-09
Sanofi Invests in Innovent to Gain Stronger Foothold in China
2022-08-05
Sosei Heptares and Abbvie Partner in Potential $1.2 Billion Neurological Disease Deal
2022-08-02
Oncology Research Collaboration between Kelun-Biotech and MSD
2022-07-27
Takeda Throws $1 Million at F-star to Develop Bispecific Antibody For Novel Cancer Therapies
2022-07-21
Roche Receives Rights to Ionis’ Antisense Kidney Disease Drug for $55 Million
2022-07-12
ADC Therapeutics and Sobi Sign $435 Million Deal to Expand Blood Cancer Drug’s Market
2022-07-11
CureVac Files mRNA Patent Lawsuit Against BioNTech in Germany
2022-07-06
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
Astellas and Sutro Team Up for Immunostimulatory Antibody-Drug Conjugates (iADCs)
2022-06-28
Amgen Out-Licenses Two Therapies to Fosun Pharma to Expand Presence in China
2022-06-28
US Court Rules Novartis Blockbuster Multiple Sclerosis Drug’s Patent Invalid
2022-06-22
1 2 3 6
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Pfizer, Sangamo Re-Opens Enrolment For Hemophilia A Gene Therapy
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!